News coverage

Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.

Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.

Adults living with unexplained cholestasis could receive a diagnosis with next generation sequencing, suggests US study.

A large US gene panel has helped to elucidate the underlying genetic basis of unexplained cholestasis.

Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.

Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.

Treatment-refractory pruritus following liver transplant may be successfully treated with IBAT inhibitors, suggests a US case series.

Raj Vuppalanchi reports findings characterizing the phenotype of women with hormonal contraceptive-associated drug-induced liver injury.

Dr Deepak Joshi and Dr Silvia Vilarinho discuss what’s ahead at AASLD 2025, focusing on late-onset genetic cholestasis and Alagille syndrome, and share what they are most looking forward to at this year’s meeting.

Ileal bile acid transporter inhibitors help treat adults with drug-induced or pregnancy-related intrahepatic cholestasis

Preclinical findings at EASL Congress 2025 point to organoid models for different types of PFIC.

Research confirms that the EASL guidelines aid risk stratification for intrahepatic cholestasis of pregnancy.

Research shows the utility of genetic testing for patients with adult-onset cholestatic disease.

Drs Richard Thompson and Verena Keitel-Anselmino discuss their cholestasis preclinical highlights from the EASL Congress 2025.

Ms Nina Rodriguez and Dr Tatyana Kushner confirm that the 2023 EASL guidelines can help risk stratify patients with intrahepatic cholestasis of pregnancy.

Research sheds light on the varying impact of ABCB4 gene variants in intrahepatic cholestasis of pregnancy and other adult-onset forms of cholestasis.

Updated results for adult participants of the PEDFIC2 trial and older children taking part in the ASSERT-EXT study.

Case studies demonstrate the utility of genetic analysis and whole-exome sequencing for the diagnosis of progressive familial intrahepatic cholestasis in patients with nonspecific liver disease.

Further findings on the efficacy and safety of ileal bile acid transporter inhibitors for patients with progressive familial intrahepatic cholestasis have been presented at the 2024 AASLD The Liver Meeting in San Diego, California, USA.

Dr Miki Scaravaglio talks through her proof-of-principle study findings for use of whole-exome sequencing to aid the diagnosis of people with adult-onset cholestatic liver disease.

Whole-exome sequencing led to definitive diagnoses for almost a quarter of patients with unexplained adult-onset cholestatic liver disease, say Italian researchers.

Dr Andrew Stolz reports on the relationship between alterations to the ABCB11 gene and the risk of drug-induced liver injury from anabolic steroids.

Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.

Alterations to ABCB11 play a “pivotal role” in the development of drug-induced liver injury from anabolic steroids, US researchers reported at the 2024 AASLD The Liver Meeting in San Diego, California, USA.

Trial findings suggest that the IBAT inhibitor odevixibat does not prevent absorption of combined oral contraceptives in healthy women.

An EASL expert panel has developed clinical practice guidelines for the management of progressive familial intrahepatic cholestasis and other genetic cholestatic liver diseases.